The Princess Margaret Cancer Foundation
Dr. Pamela Ohashi is the Co-Director of the Tumor
Immunotherapy Program (TIP). Her laboratory
has made key contributions to our understanding
of the immune system, and she spearheaded the
establishment of the first Adoptive T-cell Therapy
clinical trial in Canada.
Dr. Lillian Siu is a senior staff medical oncologist and
a recognized world leader in the management of
Phase I and II clinical trials. She is Co-Director of the
Tumor Immunotherapy Program, Co-Director of the
BRAS Drug Development Program, and Executive
Director of the Cancer Genomics Program. Together,
the three programs of tumor immunotherapy, drug
development and cancer genomics form a triad of
synergy that supports The Princess Margaret’s core
vision to deliver Personalized Cancer Medicine.
Dr. Marcus Butler is a senior medical oncologist and
Director of the Immune Monitoring Laboratory.
Before joining The Princess Margaret, Dr. Butler was
an Instructor in Medicine at Harvard Medical School
and a Clinical Fellow in Medicine at the Dana-Farber
Cancer Institute. As a clinician-scientist, Dr. Butler
plays a leadership role in translating the discoveries
in our laboratories into clinical trials that have the
potential to improve outcomes for patients.
Dr. Tak Mak changed the world of medical research
in 1984 when he published a landmark scientific
paper on the cloning of the T-cell receptor gene,
considered the ‘holy grail’ of the human immune
system. He is the Director of The Campbell Family
Institute for Breast Cancer Research, and was invited
to the Vatican this year, along with several other
world-leading cancer researchers, to take part in a
conference that focused in part on immunotherapy.